|Bid||48.20 x 1800|
|Ask||60.85 x 1800|
|Day's Range||47.10 - 49.05|
|52 Week Range||11.40 - 62.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.00|
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...
Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $52.00 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, are expected to be $312,000,000. Zogenix has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are being sold by Zogenix.
The Emeryville, California-based company said it had a loss of 83 cents per share. Losses, adjusted to account for discontinued operations, were 82 cents per share. The results beat Wall Street expectations. ...
Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are to be sold by Zogenix.
Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome anticipated ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Zogenix, Inc. (NASDAQ: ZGNX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To listen ...
The awards were made on August 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. The inducement awards consist of options to purchase an aggregate of 32,000 shares of Zogenix common stock. The options have a ten-year term and an exercise price equal to $56.20, the fair market value of Zogenix common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).
EMERYVILLE, Calif., Aug. 01, 2018-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system disorders, today announced that it will report its financial ...
A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.
Cardiac monitoring is a $32 billion market, and the companies that are successfully navigating this space with new technology are seeing huge returns: IRTC is up 300% in 3 years, and BEAT up 800% in 5 years. Biotricity (BTCY) is the most recent entrant into the remote monitoring space with their first FDA clearance in December. The launch of Bioflux, an advanced remote ECG monitoring device, is underway and first sales should emerge in the coming months after having signed some respected anchor clients.
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX).
While the Dow reclaimed its above 25,000 levels after almost a month Nasdaq is at a record high. The Dow Jones Industrial Average gained 0.38 percent to close at 25,019.41, while the S&P 500 Index increased 0.11 percent to close at 2,801.31. The Nasdaq Composite Index climbed 0.03 percent to close at 7,825.98.
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / An analyst at Cantor Fitzgerald thinking that Galmed Pharmaceuticals is undervalued in the NASH space had traders cheering on Thursday, sending shares higher ...
Today, Zogenix stock is trading at $55.72, which represents a ~20.35% rise from yesterday’s close of $46.30. Zogenix also hit a 52-week high of $58.30 today, and yesterday’s closing price was ~361% higher than its 52-week low of $10.05 on August 11, 2017.